000 05687cam a2200433Ki 4500
988 _aSpringer_Medicine_2017
999 _c96457
_d96457
_x1
001 96457
003 ES-MaUEC
005 20230102112754.0
006 m o d
007 cr |n|||||||||
008 170830s2017 sz ob 001 0 eng d
020 _a3319599631
_q(electronic bk.)
020 _a9783319599632
_q(electronic bk.)
020 _z3319599623
020 _z9783319599625
040 _aYDX
_beng
_cYDX
_dN$T
_dEBLCP
_dGW5XE
_dN$T
_dDKU
_dUAB
_dAZU
_dUPM
_dOCLCF
_dMERER
_dOCLCQ
_dESU
_dIOG
_dCOO
_dES-MaUEC
_bspa
050 4 _aRC927
_b2017 EB
245 0 0 _aComorbidity in rheumatic diseases
_cYasser El Miedany, editor.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
500 _a
504 _aIncluye referencias bibliográficas e índice
505 0 _aDedication; Foreword; Preface; Contents; Contributors; Chapter 1: Comorbidity in Rheumatic Diseases; Cardiovascular Disease in Rheumatic Disease; Epidemiology; Pathophysiology; Risk Factors; Assessment and Prediction; CV Risk Management; Infection in Rheumatic Diseases; Site-Specific Infections; Corticosteroids and Risk of Infection; Key Recommendations for Clinical Practice; Malignancy in Rheumatic Diseases; Malignancy and Systemic Lupus Erythematous; Malignancy and Rheumatoid Arthritis; Malignancy and Systemic Sclerosis; Malignancy and Inflammatory Myopathies
505 8 _aEffect of Comorbidity on Physical Function Comorbidity and Disease Outcomes; Medical Guidelines and Comorbidities; Management of Comorbidities; Screening; Conclusion; References; Chapter 3: Rheumatoid Arthritis; Cardiovascular Disease; Pericardial Disease; Ischaemic Heart Disease; Cardiomyopathy; Congestive Cardiac Failure; Valve Disease; Arrhythmia Including QT Effects of Drugs; Hypertension; Stroke and Peripheral Vascular Disease; Thromboembolic Disease; Respiratory Disease; Interstitial Lung Disease; Subtypes of ILD; Treatment of ILD in RA
505 8 _aMalignancy and Sjögren's Syndrome DMARDs and Malignancy; Rheumatic Disease and Osteoporosis; Insulin Resistance and Rheumatic Diseases; Interstitial Lung Diseases in Rheumatic Diseases; Anemia in Rheumatic Diseases; Comorbidity Pattern, Effect on Outcomes, and Recommendations for Clinical Practice; References; Chapter 2: Impact of Comorbidity; Comorbidity in Rheumatic Diseases; Prevalence; Multidimensional Impact of Comorbidity; Impact on Prescribing Medications; Financial Impact; Impact on Clinical Research; Effect of Comorbidity on Mortality
505 8 _aPsychosis Impact of Comorbidities in RA; Assessment and Management of Comorbidities in RA; Conclusion; References; Chapter 4: Psoriasis; Inflammatory Pathway: "The Psoriatic March" from Gene to Clinic; Psoriatic Arthritis; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Inflammatory Bowel Disease; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Obesity; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Diabetes Mellitus/Insulin Resistance; Background and Pathophysiology
505 8 _aTreatment Considerations in ILD Airways Disease; Bronchiectasis; Pleural Disease; Pulmonary Nodules; Malignancy; Cancers and Rheumatoid Arthritis; Solid Cancers; Skin Cancers; Lymphoma; Monitoring for Malignancy and Routine Care; Management of Patients Who Develop Malignancy During Treatment; Infections; Nonbiologic DMARDs and Infections; Biologics and Infections; Viral Hepatitis and Rheumatoid Arthritis; HIV and Rheumatoid Arthritis; Rheumatoid Vasculitis; Secondary MSK Disease; Osteoporosis; Osteoarthritis; Fibromyalgia; Psychological Comorbidity; Depression; Anxiety
520 3 _aThis book explores comorbidity in patients with rheumatic diseases and details both care and treatment options in standard clinical practice.Patients with rheumatic diseases are clinically complex, and the interplay of their disease activity with associated conditions may lead to increased morbidity and mortality. Recently there have been major advances in the management of rheumatic diseases, however, without addressing the potential comorbid conditions, including cardiovascular disease; pulmonary disease; and depression; outcomes remain poor. With its 19 chapters, covering the management of major rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus , and osteoarthritis), potential comorbidities and treatment recommendations, as well as possible interactions between conditions; this book addresses the gap between textbook medicine and day to day patients' care. Authors also discuss the new hot issue of the comorbidity index, comparing the standard tools to the recently developed indices and how they can assist the rheumatologists in determining disease burden, prognosis, and comorbidity probability. This book is an ideal clinical guide and reference that enables rheumatologists, internal medicine physicians, and residents to address the full clinical expression of these rheumatic diseases with views towards prevention or early management of comorbid conditions. .
650 7 _aReumatismo
_2embne
_9138755
700 1 _aEl Miedany, Yasser.
_995181
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-59963-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI